Insmed Inc. (NASDAQ:INSM) Q1 2022 Results Conference Call May 5, 2022 8:30 AM ET

Company Participants

Eleanor Barisser - IR

Will Lewis - Chairman, CEO

Sara Bonstein - CFO

Conference Call Participants

Andrea Tan - Goldman Sachs

Anita Dushyanth - Berenberg

Jeff Hung - Morgan Stanley

Jennifer Kim - Cantor Fitzgerald

Jessica Fye - JPMorgan

Joseph Schwartz - SVB Securities

Judah Frommer - Credit Suisse

Ritu Baral - Cowen

Stephen Willey - Stifel

Operator

Hello, everyone, and welcome to the Insmed First Quarter 2022 Financial Results Call. My name is Daisy, and I'll be coordinating today's call. [Operator Instructions]

I will now hand the call over to your host, Eleanor Barisser, Investor Relations at Insmed to begin. So Eleanor, please, go ahead.

Eleanor Barisser

Thank you, Daisy. Good morning, and welcome to today's conference call to discuss our first quarter financial results for 2022 and provide a business update. Before we start, let me remind you that today's call will include forward-looking statements based on current expectations. Such statements represent our judgment as of today and may involve risks and uncertainties that may cause actual results to differ materially from the results discussed in the forward-looking statements.

Please refer to our filings with the Securities and Exchange Commission, which are available through the SEC's website at www.sec.gov, or from our website information concerning the risk factors that could affect the company. The information on today's call is not intended for promotional purposes and it is not sufficient for prescribing decisions.

Joining me on today's call are members of the Insmed executive management team, including Will Lewis, Chair and Chief Executive Officer; and Sara Bonstein, Chief Financial Officer. Insmed business is currently segmented into 4 pillars: ARIKAYCE, Brensocatib, TPIP and Translational Medicine. We will keep our prepared remarks brief on today's call, focusing on the key activities and milestones within each of these 4 pillars, followed by a financial overview.

Let me now turn the call over to Will Lewis for prepared remarks. Upon completion of those remarks, we will open the call up for your questions.

Will Lewis

Thank you, Eleanor, and good morning, everyone. Insmed had a strong start to 2022, marked by continued execution across our 4 pillars. All of our prior guidance remains intact, and we are executing effectively across our global operations.

This is evidenced by strong first quarter revenue growth of 32% year-over-year during what is typically our most challenging quarter, giving us continued confidence in our anticipated growth of at least 30% this year. Let's start with our first pillar, ARIKAYCE, our marketed product for the treatment of refractory NTM lung disease. ARIKAYCE is also being explored in a frontline clinical trial program consisting of the ARISE and the ENCORE trials, which we believe will support full FDA and select international approvals of ARIKAYCE for newly diagnosed NTM patients. Enrollment in the ARISE study remains on track, and we still anticipate reaching full enrollment this year with top line data to follow in the first half of next year.